Axsome Therapeutics (NASDAQ:AXSM) Director Mark Coleman Purchases 1,575 Shares

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman acquired 1,575 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were bought at an average price of $127.28 per share, with a total value of $200,466.00. Following the transaction, the director directly owned 48,212 shares in the company, valued at approximately $6,136,423.36. The trade was a 3.38% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $125.68 on Wednesday. The company’s fifty day moving average is $111.18 and its two-hundred day moving average is $110.83. The company has a quick ratio of 1.51, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. Axsome Therapeutics, Inc. has a 12-month low of $75.56 and a 12-month high of $139.13. The company has a market cap of $6.27 billion, a P/E ratio of -24.79 and a beta of 0.54.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.08. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The company had revenue of $150.04 million for the quarter, compared to the consensus estimate of $140.02 million. Equities analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Moors & Cabot Inc. boosted its position in shares of Axsome Therapeutics by 4.5% during the second quarter. Moors & Cabot Inc. now owns 2,330 shares of the company’s stock worth $243,000 after purchasing an additional 100 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Axsome Therapeutics by 1.1% during the second quarter. China Universal Asset Management Co. Ltd. now owns 9,889 shares of the company’s stock worth $1,032,000 after purchasing an additional 107 shares in the last quarter. Mutual of America Capital Management LLC lifted its position in Axsome Therapeutics by 0.3% in the 1st quarter. Mutual of America Capital Management LLC now owns 39,623 shares of the company’s stock valued at $4,621,000 after acquiring an additional 136 shares in the last quarter. Assetmark Inc. lifted its position in Axsome Therapeutics by 13.9% in the 2nd quarter. Assetmark Inc. now owns 1,124 shares of the company’s stock valued at $117,000 after acquiring an additional 137 shares in the last quarter. Finally, Profund Advisors LLC lifted its position in Axsome Therapeutics by 4.6% in the 2nd quarter. Profund Advisors LLC now owns 4,063 shares of the company’s stock valued at $424,000 after acquiring an additional 180 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AXSM. Bank of America increased their price objective on Axsome Therapeutics from $173.00 to $176.00 and gave the stock a “buy” rating in a report on Tuesday, August 5th. Needham & Company LLC reiterated a “buy” rating and set a $150.00 price objective on shares of Axsome Therapeutics in a report on Monday, August 4th. HC Wainwright reiterated a “buy” rating and set a $180.00 price objective on shares of Axsome Therapeutics in a report on Tuesday, June 10th. Morgan Stanley initiated coverage on shares of Axsome Therapeutics in a research report on Thursday, July 3rd. They set an “overweight” rating and a $190.00 target price on the stock. Finally, Oppenheimer assumed coverage on shares of Axsome Therapeutics in a research report on Tuesday, June 3rd. They set an “outperform” rating and a $185.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating and thirteen have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $177.86.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.